Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tandem Diabetes Care (TNDM) EBIT Margin (2016 - 2025)

Tandem Diabetes Care's EBIT Margin history spans 13 years, with the latest figure at 2.86% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 306.0% year-over-year to 2.86%; the TTM value through Dec 2025 reached 18.45%, down 791.0%, while the annual FY2025 figure was 18.45%, 791.0% down from the prior year.
  • EBIT Margin reached 2.86% in Q4 2025 per TNDM's latest filing, up from 9.17% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 6.07% in Q4 2021 to a low of 75.46% in Q1 2023.
  • Average EBIT Margin over 5 years is 14.54%, with a median of 9.93% recorded in 2024.
  • Peak YoY movement for EBIT Margin: tumbled -6674bps in 2023, then soared 5372bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 6.07% in 2021, then plummeted by -233bps to 8.06% in 2022, then tumbled by -121bps to 17.82% in 2023, then skyrocketed by 99bps to 0.21% in 2024, then skyrocketed by 1490bps to 2.86% in 2025.
  • Per Business Quant, the three most recent readings for TNDM's EBIT Margin are 2.86% (Q4 2025), 9.17% (Q3 2025), and 21.53% (Q2 2025).